Proteasome Ligand

RAPRMT5 is a PRMT5 CAP-TAC (proteinase complex-targeted chimeric agent) degrader. RAPRMT5 can induce PRMT5 to undergo proteasome-dependent, ubiquitin-independent degradation. RAPRMT5 can be used in the research of various cancers.

Biotin-epoxomicin is a Proteasome subunit binder. Biotin-epoxomicin serves as an affinity reagent for identifying proteasomal catalytic subunits, and facilitates affinity purification of active proteasomal subunits for LC-MS identification. Biotin-epoxomicin can be used to study solid tumors derived from B16 melanoma.

RA183 is a proteasome ligand that can be used to synthesize CAP-TAC (proteasome cap-targeted chimera), such as RAPRMT5 (HY-181521).

RA183-CO-C6-NHCO-NH-Boc is a proteasome ligand-linker conjugate that can be used for the synthesis of CAP-TAC (proteasome cap-targeted chimera), such as RAPRMT5 (HY-181521).

RAFKBP12 is a FKBP12 CAP-TAC (proteinase complex cap-targeted chimera) degrader. RAFKBP12 demonstrates the feasibility of the CAP-TAC strategy, which enables proteasome-dependent degradation of FKBP12 that is independent of E3 ubiquitin ligases and protein ubiquitination.